Insilico Medicine, an AI‑driven clinical‑stage biotech, was added to the Hang Seng Composite Index (HSCI) and became eligible for the Stock Connect program, expanding its investor access in Hong Kong markets. The lead sentence: the index inclusion recognizes Insilico’s market footprint and can widen capital channels for AI‑enabled drug discovery companies. The move underscores investor appetite for generative AI platforms in life sciences and may increase institutional flows and regional partnerships for the firm.